Asarina Pharma (ASAP.ST) Stock Analysis & AI Equity Report
Asarina Pharma (ASAP.ST) overview
Asarina Pharma (ASAP.ST) stock analysis and AI equity research. For the latest completed financial year, 2023, Asarina Pharma reported revenue of SEK 0m and operating profit of SEK -14.6m; the year-end share price was 0.88 SEK and market capitalisation was SEK 19.9m. Asarina Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Asarina Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-08-30. Data will be refreshed during report generation.
About Asarina Pharma
Asarina Pharma AB (publ) is a Swedish biotechnology company that developed Sepranolone for stress-, compulsion- and menstrual-related disorders, including Tourette syndrome, PMDD and menstrual migraine. The company also built a broader GAMSA neurosteroid platform. Following a decision to enter voluntary liquidation, it sold its Sepranolone intellectual property and is winding down remaining operations.
Generate the Asarina Pharma report
Asarina Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Asarina Pharma and represent the latest completed financial year (2023). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.